Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s 2005 New Molecular Entity Total: 18, Including Five In December

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA clearance of Bayer/Onyx’ Nexavar oncologic Dec. 20, ahead of its Jan. 11, 2006 user fee goal date, helped the agency achieve a total of 18 new molecular entity approvals in 2005.
Advertisement

Related Content

New Molecular Entities Approved In 2010
New molecular entities that aren’t new to the market
Nexavar priority review for liver cancer
Astellas Vaprisol supplemental approval
Approvals In Brief
NDA Receipt Total Of 116 In 2005 Affirms Modest Growth Since Millennium
Revlimid Lax Teratogenicity Studies Led To Broad Risk Management Plan – FDA
U.S. Surpasses Europe As First-Launch Locale, Top Drug Innovator – Study
Year-End Submission Rate Stabilizes In 2005 As NDA Approvals Drop
Year-End Submission Rate Stabilizes In 2005 As NDA Approvals Drop

Topics

Advertisement
UsernamePublicRestriction

Register

PS003166

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel